Gut & Digestive Health

Gut & Digestive Health
  • A Longer Wait Before the Next Colonoscopy Held Its Own Against the Usual Schedule

    CATEGORY: GUT & DIGESTIVE HEALTH

    The earlier repeat colonoscopy didn’t buy extra protection. Among 10,799 adults who’d had higher-risk colon polyps removed, those scheduled for their first follow-up exam at five years developed colorectal cancer at almost exactly the same rate as those rechecked at three: 0.77% versus 0.82% over five and a half years, meeting the trial’s bar for the longer wait being no worse.1 The five-year schedule needed 4,434 colonoscopies where the three-year schedule needed 8,614, close to half as many.

    Why the Calendar Matters After Polyps

    Most colorectal cancers grow from polyps, small growths on the bowel wall, over many years. When a colonoscopy finds and removes the riskier kind, a large one, one with worrisome cells, or three or more at once, guidelines in the US and Europe have generally called people back within about three years. That interval was set decades ago. Scopes and removal tools have improved since. Each extra exam carries a day of prep, sedation, a small risk of complications, and real cost, multiplied across millions of people with polyp findings every year.

    Eight Countries, a Coin-Flip Schedule, Cancer as the Yardstick

    Adults aged 40 to 74 in eight European countries were randomly scheduled for a first surveillance exam at either three or five years after their polyps came out; the three-year group was scoped again at five. Cancer registries and the five-year exams then settled the outcome. More than 99% in both groups stayed cancer-free. Deaths from colorectal cancer were vanishingly rare in each, three in one group, two in the other. The shorter schedule did find more new polyps. Whether finding them earlier helps anyone is exactly what the trial’s authors say remains to be seen.

    An Answer at Five Years, a Fuller One at Ten

    This is a planned interim look. The trial’s primary endpoint is cancer incidence at ten years, so the final word arrives later, and about a third of participants hadn’t completed their five-year exam on schedule, which blurs the comparison somewhat. Still, the investigators note the result may encourage guideline committees to reconsider the three-year reflex, and an accompanying editorial weighs the same question. For a procedure this common, halving its frequency without measurable harm is a result with wide reach.

    Key Takeaways

    • Colorectal cancer rates after higher-risk polyp removal were essentially the same whether the first follow-up colonoscopy came at three years or five: 0.82% versus 0.77%.
    • The longer interval meant roughly half as many colonoscopies, with no detected cost in cancers or cancer deaths so far.
    • This is an interim result from a trial that reads out fully at ten years, and current guidelines still recommend the shorter interval.

    References

    1. Jover R, et al. Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal. The New England Journal of Medicine. 2026; DOI 10.1056/NEJMoa2603816. link

    More from Gut & Digestive Health!


  • A Drug Best Known for Psoriasis Put More Ulcerative Colitis Patients Into Remission

    A drug that has spent years clearing psoriasis plaques just posted its numbers in a different fight. In two linked phase 3 trials, half of the people with moderate to severe ulcerative colitis who kept taking guselkumab every four weeks… Read More →


  • Donor Stool Transplants Came Up Short in Irritable Bowel Syndrome

    If you live with irritable bowel syndrome, you've probably run into the promise that fixing your gut bacteria could fix your gut. The most rigorous test of that idea has now reported, and the promise didn't hold. Among 450 Norwegian… Read More →


  • A Next-Generation Stool Test Caught More Colon Cancers Than the Standard Home Kit

    If you've been putting off a colonoscopy, the alternative usually arrives as a small kit in the mail. Among 20,176 U.S. adults who tried both kinds of kit before a screening colonoscopy, a next-generation stool DNA test—marketed under the brand… Read More →


  • The First Approved Fatty Liver Medicine Improved Both Inflammation and Scarring

    Until 2024, a common liver disease had no approved medicine at all. The tablet that ended that run, resmetirom, earned its approval by clearing the disease's hallmark inflammation in up to 29.9% of patients against 9.7% on placebo, and improving… Read More →


  • Risankizumab Topped Ustekinumab at Healing the Gut in Crohn’s Disease

    Risankizumab healed the intestinal lining in 31.8% of Crohn's patients at one year, against 16.2% on ustekinumab, an adjusted gap of 15.6 percentage points. It proved no worse on symptom relief either, with 58.6% against 39.5% reaching clinical remission at… Read More →


  • Semaglutide Improved Liver Inflammation and Scarring in Advanced Fatty Liver Disease

    Weekly semaglutide injections cleared the inflammation out of the liver in 62.9% of adults whose fatty liver disease had already progressed to scarring, against 34.3% of those given a placebo over 72 weeks. Measurable scarring improved in 36.8% on the… Read More →


  • A Mediterranean-Style Diet Beat Standard Advice for Irritable Bowel Symptoms

    The researchers had a modest goal. Their trial was built to show that a Mediterranean-style diet was no worse than the standard first-line dietary advice for irritable bowel syndrome. It cleared that bar and kept going. Among 139 UK adults… Read More →


  • Low-Dose Aspirin Cut Recurrence in PI3K-Altered Colorectal Tumors

    Aspirin has long been suspected of holding colorectal cancer at bay, and the ALASCCA trial asked a sharper version of the question: in whose tumors? Researchers screened 2,980 tumors for alterations in the PI3K signaling pathway, then randomized 626 patients… Read More →


  • Home Stool Testing Matched Colonoscopy for Preventing Colon Cancer Deaths

    Can a kit used at the kitchen table do the job of a camera in a procedure room? A randomized trial of more than 57,000 Spanish adults aged 50 to 69 put the two screening offers side by side. After… Read More →